Video

Dr. Skarbnik on the Approval of Brexucabtagene Autoleucel in MCL

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, discusses the approval of brexucabtagene autoleucel (Tecartus) in ​relapsed/refractory mantle cell lymphoma (MCL).

On July 24, 2020, the FDA approved the CAR T-cell therapy brexucabtagene autoleucel for patients with ​relapsed/refractory MCL based on findings from the ​phase 2 ZUMA-2 study, says Skarbnik.

The ZUMA-2 trial evaluated brexucabtagene autoleucel in patients with relapsed/refractory MCL who previously received a BTK inhibitor​, Skarbnik says. Notably, the CAR T-cell product induced an 87% objective response rate and a 62% complete response rate in this patient population. 

​However, the regulatory decision does not require ​patients to have had prior exposure to a BTK inhibitor, ​explains Skarbnik.

Although BTK inhibitors offer an effective therapy for patients with relapsed/refractory MCL, the majority of responses do not exceed 26 months, Skarbnik explains.

As such, ​the decision to approve brexucabtagene autoleucel for all patients with relapsed/refractory MCL may allow more patients to derive extended responses, concludes Skarbnik.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity